Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Familial amyloidosis, Finnish type


Other Names for this Disease

  • Amyloidosis, Meretoja type
  • Amyloid cranial neuropathy with lattice corneal dystrophy
  • Amyloidosis V
  • Familial amyloid polyneuropathy type IV
  • Hereditary gelsolin amyloidosis
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Your Question

I am curious of what to expect with this type, and the age of onset of symptoms.

Our Answer

We have identified the following information that we hope you find helpful. If you still have questions, please contact us.

What are the signs and symptoms of familial amyloidosis, Finnish type?

Symptoms of this condition usually begin in an individual's 20s or 30s, and they usually emerge in a specific order. The progression is often slow, but varies among individuals. The typical triad of features includes accumulation of amyloid deposits in the cornea (lattice corneal dystrophy), cutis laxa (sagging skin), and nervous system symptoms (neuropathy).[1][2]

Eye symptoms typically begin first. The amyloid deposits cloud the cornea, often leading to vision impairment.[2] Other eye symptoms may include dryness, irritation and light sensitivity. Affected individuals may eventually develop cataracts and glaucoma.[1]

As the condition progresses, the nerves become involved (typically in an individual's 40s). Dysfunction of the nerves in the head and face (cranial nerves) causes paralysis of facial muscles and decreased sensation, which can lead to difficulty speaking, chewing, and swallowing.[2] Facial paralysis can also cause additional eye symptoms including ectropium (turning out of the eyelid), corneal ulcers, or droopy eyelids (ptosis).[1] Affected individuals may also have peripheral neuropathy.[2] Central nervous system symptoms such as impaired cognitive function are rare but have been reported in older individuals.[1]

Skin manifestations may also begin in a person's 40s and include a thickened, sagging appearance and cutis laxa (loose skin that lacks elasticity), especially on the face.[1][2] Cutis laxa worsens with age.[1]

Other signs and symptoms that have been reported in some people include gastric motility changes, orodental problems, heart palpitations, cardiac conduction problems, and mild proteinuria.[1]
Last updated: 11/20/2013

What is the long-term outlook for individuals with familial amyloidosis, Finnish type?

Symptoms of this condition usually begin in an individual's 20s or 30s, and they usually emerge in a specific order. Eye-related symptoms typically begin first, followed by nerve and skin manifestations in an individual's 40s.[1][2] Because of the rarity of the condition, the frequency with which each symptom occurs is not exactly known.[3] The condition is progressive, meaning that symptoms worsen with age. Progression is often slow, but the rate varies among affected individuals.[1][2]

In the later stages of the condition, individuals may have amyloid deposition in small blood vessels and vital organs, such as the kidney and heart; this can become life threatening. The mortality rate in affected individuals is thought to be slightly higher than in unaffected individuals; however, because the condition is so rare, conclusive studies regarding these statistics have not been performed. The primary causes of death in affected individuals are typically nephrotic syndrome; pneumonia from aspiration due to dysfunction of the bulbar muscles (those of the mouth and throat); or cerebral hemorrhage, likely from cerebral angiopathy (amyloid in the arteries of the brain).[3]
Last updated: 11/20/2013

References
  • Tiia Pihlamaa, Sinikka Suominen, Sari Kiuru-Enari. Familial amyloidotic polyneuropathy type IV – gelsolin amyloidosis. Amyloid. June, 2012; 19(S1):30–33. Accessed 11/18/2013.
  • Lattice corneal dystrophy type II. Genetics Home Reference. April, 2012; http://ghr.nlm.nih.gov/condition/lattice-corneal-dystrophy-type-ii. Accessed 11/18/2013.
  • Solomon JP, Page LJ, Balch WE, Kelly JW. Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention. Crit Rev Biochem Mol Biol. May-June, 2012; 47(3):282-296. Accessed 11/20/2013.
Other Names for this Disease
  • Amyloidosis, Meretoja type
  • Amyloid cranial neuropathy with lattice corneal dystrophy
  • Amyloidosis V
  • Familial amyloid polyneuropathy type IV
  • Hereditary gelsolin amyloidosis
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.